Corcept Therapeutics

CORTApproved

Menlo Park, United StatesFounded 1998corcept.com

Corcept Therapeutics is a leader in cortisol modulation science, with over 25 years of research and the discovery of more than 1,000 proprietary selective cortisol modulators. The company's mission is to unlock the potential of cortisol modulation to revolutionize the treatment of serious diseases, supported by a robust pipeline with more than 30 ongoing studies across endocrinology, oncology, metabolism, and neurology. With its first FDA-approved product generating revenue and multiple late-stage clinical programs, Corcept is positioned to expand its impact significantly in the coming years.

Market Cap

$3.7B

Founded

1998

Employees

400+

Focus

Small Molecules

CORT · Stock Price

USD 34.64+10.67 (+44.51%)

Historical price data

AI Company Overview

Technology Platform

Discovery and development of selective cortisol modulators—small-molecule drugs that precisely regulate cortisol activity at the glucocorticoid receptor (GR) to treat serious disorders.

Pipeline Snapshot

71 drugs in pipeline, 14 in Phase 3

Drug	Indication	Stage
Mifepristone 300 MG [Korlym] + Placebo for mifepristone	Hypercortisolism	Approved
Nab-paclitaxel 80 mg/m^2 + Relacorilant 150 mg once daily (QD) + Nab-paclitaxel ...	Ovarian Neoplasm	Phase 3
Mifepristone	Depressive Disorder, Major	Phase 3
Mifepristone + matching placebo	Major Depressive Disorder	Phase 3
Mifepristone + placebo	Major Depressive Disorder	Phase 3

Funding History

Total raised: $65M

IPO$40MUndisclosedJun 24, 2004

Series A$20MUndisclosedJun 15, 2000

Seed$5MUndisclosedJun 15, 1998

FDA Approved Drugs

KORLYMNDAFeb 17, 2012

Opportunities

Corcept's primary growth opportunities lie in securing regulatory approval and successfully commercializing relacorilant for Cushing syndrome and platinum-resistant ovarian cancer, which could significantly expand its revenue base.

Additionally, the development of miricorilant in the vast MASH market and exploration of GR modulation in neurology (e.g., ALS) represent substantial long-term value drivers.

Risk Factors

Key risks include clinical trial failures for late-stage assets like relacorilant, regulatory setbacks, intense competition in target markets like oncology and MASH, and over-reliance on a single platform technology.

The company's valuation is highly sensitive to pipeline catalysts.

Competitive Landscape

Corcept faces competition in endocrinology from other Cushing syndrome therapies (e.g., Signifor, Isturisa), in oncology from a range of chemotherapies and targeted agents, and in MASH from newly approved drugs and a crowded pipeline. Its differentiation is its first-mover, deep expertise in selective GR modulation and a pipeline designed to improve outcomes in combination with standard-of-care therapies.

Publications

Pipeline

FDA Approvals